Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Subscribe To Our Newsletter & Stay Updated